

Reference number
2273-H

SPECIALTY QUANTITY LIMIT PROGRAM

RASUVO (methotrexate injection)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Rasuvo (methotrexate injection) single-dose auto-injector for subcutaneous injection in 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, and 30 mg	4 injections per 28 days	<p>Rheumatoid arthritis</p> <ul style="list-style-type: none"> 7.5 mg every week (adjust gradually to achieve an optimal response); up to 20 mg per week <p>Polyarticular juvenile idiopathic arthritis</p> <ul style="list-style-type: none"> 10 mg per m² every week (adjust gradually to achieve an optimal response); up to 20 mg per m² per week <p>Psoriasis</p> <ul style="list-style-type: none"> 10 to 25 mg every week (adjust gradually to achieve an optimal response); up to 30 mg per week

III. REFERENCE

- Rasuvo [package insert]. Chicago, IL: Medac Pharma Inc.; March 2018.